Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

References

• Abernethy DR, Divoll M, Ochs HR, Ameer B, Greenblatt DJ. Increased metabolic clearance of acetaminophen with oral contraceptive use. Obstetrics and Gynecology 1982; 60(3)338–341
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clinical Pharmacokinetics 2005; 44(10)989–1008
   PubMed Web of Science ®Google Scholar
• Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. European Journal of Clinical Pharmacology 1995; 48(2)161–166
   PubMed Web of Science ®Google Scholar
• Barkhem T, Haldosen LA, Gustafsson JA, Nilsson S. pS2 Gene expression in HepG2 cells: complex regulation through crosstalk between the estrogen receptor alpha, an estrogen-responsive element, and the activator protein 1 response element. Molecular Pharmacology 2002; 61(6)1273–1283
   PubMed Web of Science ®Google Scholar
• Beaulac-Baillargeon L, Rocheleau S. Paracetamol pharmacokinetics during the first trimester of human pregnancy. European Journal of Clinical Pharmacology 1994; 46(5)451–454
   PubMed Web of Science ®Google Scholar
• Becker KL. Principles and practice of endocrinology and metabolism. Lippincott Williams & Wilkins., Philadelphia 2001; xxxiv–2477
   Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins., Philadelphia, PA 2002; xxv–1595
   Google Scholar
• Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, Peek MJ, Rowan JA, Walters BN. The detection, investigation and management of hypertension in pregnancy: executive summary. Australia New Zealand Journal of Obstetrics and Gynaecology 2000; 40(2)133–138
   PubMed Web of Science ®Google Scholar
• Carlson KE, Brandes SJ, Pomper MG, Katzenellenbogen JA. Uptake of three [3H]progestins by target tissues in vivo: implications for the design of diagnostic imaging agents. International Journal of Radiation Applications Instrumentation Part B Nuclear Medicine and Biology 1988; 15(4)403–408
   PubMedGoogle Scholar
• Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Letters 1995; 92(1)39–47
   PubMed Web of Science ®Google Scholar
• Choi S, Jeong H, Deyo K, Fischer J. Protein binding of labetalol in pregnancy. Clinical and Pharmacological Therapy 2007; 81(S1)S79
   Google Scholar
• Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Practices in Research in Clinical Obstetrics and Gynaecology 2001; 15(6)819–826
   PubMed Web of Science ®Google Scholar
• De Wildt SN, Kearns GL, Leeder JS, Van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clinical Pharmacokinetics 1999; 36(6)439–452
   PubMed Web of Science ®Google Scholar
• Donnelly R, Macphee GJ. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. Clinical Pharmacokinetics 1991; 21(2)95–109
   PubMed Web of Science ®Google Scholar
• Eisenfeld AJ, Aten RF. Estrogen receptors and androgen receptors in the mammalian liver. Journal of Steroid Biochemistry 1987; 27(4–6)1109–1118
   PubMedGoogle Scholar
• Fromm MF, Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, Eichelbaum M. Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 1997; 72(1–2)261–267
   PubMed Web of Science ®Google Scholar
• Gallery ED. Hypertension in pregnancy. Practical management recommendations. Drugs 1995; 49(4)555–562
   PubMed Web of Science ®Google Scholar
• Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, Foster BC, Cameron DW. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. British Journal of Clinical Pharmacology 1999; 48(2)168–179
   PubMed Web of Science ®Google Scholar
• Gerdin E, Salmonson T, Lindberg B, Rane A. Maternal kinetics of morphine during labour. Journal of Perinatal Medicine 1990; 18(6)479–487
   PubMed Web of Science ®Google Scholar
• Goa KL, Benfield P, Sorkin EM. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 1989; 37(5)583–627
   PubMed Web of Science ®Google Scholar
• Hardman J, Endres L, Fischer P, Fischer J. Pharmacokinetics of labetalol in pregnancy. Pharmacotherapy 2005; 25(10)1493
   Web of Science ®Google Scholar
• Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. Journal of the American Medical Association 2005; 294(21)2751–2757
   PubMed Web of Science ®Google Scholar
• King CD, Rios GR, Green MD, Tephly TR. UDP-glucuronosyltransferases. Current Drug Metabolism 2000; 1(2)143–161
   PubMed Web of Science ®Google Scholar
• Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clinical Pharmacology and Therapy 2000; 68(2)151–159
   PubMed Web of Science ®Google Scholar
• Lunell NO, Kulas J, Rane A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. European Journal of Clinical Pharmacology 1985; 28(5)597–599
   PubMed Web of Science ®Google Scholar
• Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Safety 2001; 24(6)457–474
   PubMed Web of Science ®Google Scholar
• Magee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. European Journal of Obstetrics, Gynecology and Reproductive Biology 2000; 88(1)15–26
   PubMed Web of Science ®Google Scholar
• Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. British Journal of Clinical Pharmacology 1976; 3(4 Suppl. 3)695–710
   PubMed Web of Science ®Google Scholar
• Martinez-Gomez MA, Sagrado S, Villanueva-Camanas RM, Medina-Hernandez MJ. Characterization of basic drug–human serum protein interactions by capillary electrophoresis. Electrophoresis 2006; 27(17)3410–3419
   PubMed Web of Science ®Google Scholar
• Masuyama H, Hiramatsu Y, Kodama J, Kudo T. Expression and potential roles of pregnane X receptor in endometrial cancer. Journal of Clinical Endocrinology and Metabolism 2003; 88(9)4446–4454
   PubMed Web of Science ®Google Scholar
• Masuyama H, Hiramatsu Y, Kunitomi M, Kudo T, MacDonald PN. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate pregnane X receptor-mediated transcription. Molecular Endocrinology 2000; 14(3)421–428
   PubMedGoogle Scholar
• Masuyama H, Hiramatsu Y, Mizutani Y, Inoshita H, Kudo T. The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Molecular Cell Endocrinology 2001; 172(1–2)47–56
   PubMed Web of Science ®Google Scholar
• Miners JO, Robson RA, Birkett DJ. Paracetamol metabolism in pregnancy. British Journal of Clinical Pharmacology 1986; 22(3)359–362
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clinical Pharmacology and Therapy 2006; 80(5)509–521
   PubMed Web of Science ®Google Scholar
• Niemeijer NR, Gerding TK, De Zeeuw RA. Glucuronidation of labetalol at the two hydroxy positions by bovine liver microsomes. Isolation, purification, and structure elucidation of the glucuronides of labetalol. Drug Metabolism and Disposition 1991; 19(1)20–23
   PubMed Web of Science ®Google Scholar
• O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, Balsley J, Bryson YJ. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. American Journal of Obstetrics and Gynecology 1993; 168(5)1510–1516
   PubMed Web of Science ®Google Scholar
• Schleicher F, Tauber U, Louton T, Schunack W. Tissue distribution of sex steroids: concentration of 17beta-oestradiol and cyproterone acetate in selected organs of female Wistar rats. Pharmacology and Toxicology 1998; 82(1)34–39
   PubMedGoogle Scholar
• Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am Journal of Obstetrics and Gynecology 1990; 162(4)960–966; , discussion, 966–967
   PubMed Web of Science ®Google Scholar
• Sugatani J, Nishitani S, Yamakawa K, Yoshinari K, Sueyoshi T, Negishi M, Miwa M. Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Molecular Pharmacology 2005; 67(3)845–855
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, Miners JO. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. British Journal of Clinical Pharmacology 2006; 61(4)427–439
   PubMed Web of Science ®Google Scholar
• Walle T, Fagan TC, Walle UK, Topmiller MJ. Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. British Journal of Clinical Pharmacology 1996; 41(4)305–309
   PubMed Web of Science ®Google Scholar
• Wang H, Wu X, Hudkins K, Mikheev A, Zhang H, Gupta A, Unadkat JD, Mao Q. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. American Journal of Physiology, Endocrinology and Metabolism 2006; 291(6)E1295–E1304
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, Maronpot RR, Negishi M. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. Journal of Biology and Chemistry 2006; 281(24)16625–16631
   PubMed Web of Science ®Google Scholar